Articles

Risk of thromboembolism in cancer patients with Port-a-Cath. Results and implications of the ONCOCIP study
Risk Factors

Risk of thromboembolism in cancer patients with Port-a-Cath. Results and implications of the ONCOCIP study

The normal experience of cancer patients who receive an implantable venous access device (Port-a-Cath) for chemotherapy infusion is not well known, nor have the risk factors associated with thromboembolism been appropriately investigated.

Read More
A talking point for the CANTOS trial
Trial Update

A talking point for the CANTOS trial

A year after the results of the CANTOS trial were first presented, they were still an important talking point at ESC Congress 2018 in Munich. They have established inflammation as another risk factor in atherosclerosis along with cholesterol.

Read More
Disseminated Intravascular coagulation in solid and hematological cancers
Basic Mechanism

Disseminated Intravascular coagulation in solid and hematological cancers

There is a clear relationship between malignancy and deranged coagulation. Patients with cancer are at high risk to present with venous thromboembolism, which occurrence in some cases may precede the diagnosis of cancer.

Read More
The present and the future of the SSC Subcommittee Hemostasis and Malignancies
News

The present and the future of the SSC Subcommittee Hemostasis and Malignancies

What is the SSC Subcommittee for Hemostasis and Malignancy up to?

Read More
Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer
Risk Factors

Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer

Cancer is a well-known risk factor for the occurrence of venous thromboembolism. In contrast, little research has been conducted into arterial thromboembolism (i.e. myocardial infarction, stroke, peripheral artery disease) in patients with cancer

Read More
Lessons from the CATCH study: beware of the risk of bleeding in neoplastic patients treated for VTE
Trial Update

Lessons from the CATCH study: beware of the risk of bleeding in neoplastic patients treated for VTE

The results of an interesting secondary analysis of the CATCH study were published recently and they are useful for a better understanding of the expectations and risks associated with the use of anticoagulants for the treatment of VTE in cancer patients.

Read More
An interview with Nicola Mutch
News

An interview with Nicola Mutch

We met with Nicola Mutch, president elect of the ISTH SCC, during the 9th ICTHIC in Bergamo.

Read More
Arterial thromboembolism can also be the first clinical manifestation of a neoplasm
Solid Tumors

Arterial thromboembolism can also be the first clinical manifestation of a neoplasm

Several studies showed that venous thrombosis can be the first clinical manifestation of an occult neoplasm.

Read More
Anticoagulant treatment in patients with thrombocytopenia and cancer-associated thrombosis
Anticoagulation Drugs

Anticoagulant treatment in patients with thrombocytopenia and cancer-associated thrombosis

One of the most complex situations in the treatment of cancer-associated thrombosis is represented by oncological patients with thrombocytopenia...

Read More
Rapping about new anticoagulants for CAT at ICTHIC 2018
Clinical

Rapping about new anticoagulants for CAT at ICTHIC 2018

Cancer patients are four or five times as likely to develop venous thromboembolism (VTE): not only does the disease increase the incidence but so do treatments such as chemotherapy and radiation. Drugs which can treat it and prevent recurrences are therefore an important part of oncology strategies.

Read More

Page 1 of 5